Polymorphism of RANTES Chemokine Gene Promoter Is Not Associated With Long-Term Nonprogressive HIV-1 Infection of More Than 16 Years
Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Cristóbal Richart(Universitat Rovira i Virgili), Enric Pedrol(Hospital General de Granollers), Hernando Knobel(Hospital General de Granollers), Cristina Gutiérrez(Hospital Universitari Joan XXIII de Tarragona), Montserrat Broch(Hospital Universitari Joan XXIII de Tarragona), Mireia Cairó(University Hospital Mútua de Terrassa), Peré Domingo(Hospital de Sant Pau), Elisabeth Deig(Hospital General de Granollers), Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), M. Montero(Universitat de València), Àngels Fontanet(Universitat Autònoma de Barcelona), David Dalmau(University Hospital Mútua de Terrassa), Ma Antònia Sambeat(Universitat Autònoma de Barcelona), Joaquim Peraire(Instituto de Salud Carlos III), Juan J. Sirvent(University of Alicante)
JAIDS Journal of Acquired Immune Deficiency Syndromes
December 7, 2005
Cited by 22
Related Papers
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
|Proceedings of the National Academy of Sciences|2022|198
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143